Business
Intrasense : Full-year results for 2024 down against a backdrop of transformation, product range expansion and strategic investments to drive tomorrow's growth
Intrasense : Full-year results for 2024 down against a backdrop of transformation, product range expansion and strategic investments to drive tomorrow's
About this update from Intrasense Sa
[{"type":"text","content":"Full-year results for 2024 down against a backdrop of transformation, product range expansion and strategic investments to drive tomorrow's growth\n A new roadmap based on 4 strategic pillars: innovation, product range extension, geographic expansion, financial control\n An evolving business model for more recurring revenues and ambitious financial targets:\n • Double-digit growth in activity in 2025\n • Order intake target exceeding €5M in 2025\n • Break-even point expected by 2027\n Montpellier, March 26, 2025, 5:45 PM - Intrasense (ISIN : FR0011179886), a French expert in medical imaging solutions facilitating diagnosis, decision-making, and therapeutic follow-up, announces the publication of its 2024 annual results and its new strategic roadmap. These financial statements were approved on March 25, 2025, by the Board of Directors. The audit procedures on the consolidated accounts have been completed, and the certification report was issued on March 26 by the statutory auditors.\n Alexandre Salvador, Intrasense CEO, states: \" The year 2024 was a decisive milestone for Intrasense, marked by the certification of six of our solutions (Myrian® 2.10, 2.12, and 2.13, Liflow® 1.0 and 2.0, DUOnco™ Liver 1.0), changes in our governance, and the deliberate continuation of necessary investments to support our future growth, all made possible by the support of our key shareholder despite a decline in our activity. Together, we have laid the foundations for a new momentum based on a vision of sustainable and structured growth. Our roadmap is built on four strategic pillars: innovation, product range expansion, geographical expansion, and financial control. Leveraging these drivers, we aim for a significant acceleration of our development, with ambitious financial targets and a shift towards a model with more recurring revenues. As early as 2025, we are targeting double-digit growth and a significant turnaround in order intake, with Liflow® and DUOnco™ solutions offered under multi-year subscription models. This new trajectory will position us to reach the break-even point by 2027. More than ever, we are convinced that our strategy and the dedication of our teams will strengthen our position in this rapidly growing market and create long-term value, both for patients and for all healthcare professionals.\"\n 2024 Results in line with a ye...